ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2022
Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS.
Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 5 citations in OpenAlex.
- AI-Powered Gradient Echo Plural Contrast Imaging (AI-GEPCI)-A Comprehensive Neurological Protocol From a Single MRI Scan.Journal of magnetic resonance imaging : JMRI · 2026Article
- AI-powered Gradient Echo Plural Contrast Imaging (AI-GEPCI) - a Comprehensive Multiparametric Neurological Protocol from a Single MRI Scan.medRxiv : the preprint server for health sciences · 2026Article
- Increased periventricular thalamic damage gradient in multiple sclerosis detected by quantitative gradient echo MRI.Multiple sclerosis and related disorders · 2024Article
- Quantitative gradient recalled echo (qGRE) MRI enables in vivo measurement of pre-atrophic neurodegeneration in a mouse model of Alzheimer's disease.NeuroImage · 2024Article
- Quantitative MRI identifies lesional and non-lesional abnormalities in MOGAD.Multiple sclerosis and related disorders · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundImaging biomarkers of progressive multiple sclerosis (MS) are needed. Quantitative gradient recalled echo (qGRE) magnetic resonance imaging (MRI) evaluates microstructural tissue damage in MS.
objectiveTo evaluate qGRE-derived R2t* as an imaging biomarker of MS progression compared with atrophy and lesion burden.
methodsTwenty-three non-relapsing progressive MS (PMS), 22 relapsing-remitting MS (RRMS), and 18 healthy control participants underwent standard MS physical and cognitive neurological assessments and imaging with qGRE, FLAIR, and MPRAGE at 3T. PMS subjects were tested clinically and imaged every 9 months over 45 months. Imaging measures included lesion burden, atrophy, and R2t* in cortical gray matter (GM), deep GM, and normal-appearing white matter (NAWM). Longitudinal analysis of clinical performance and imaging biomarkers in PMS subjects was conducted via linear models with subject as repeated, within-subject factor. Relationship between imaging biomarkers and clinical scores was assessed by Spearman rank correlation.
resultsR2t* reductions correlated with neurological impairment cross-sectionally and longitudinally. PMS patients with clinically defined disease progression (
conclusionqGRE-derived R2t* is a potential imaging biomarker of MS progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.